
Xiao Hong Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4028173/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 441-445.	7.0	21
2	FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 1220-1226.	7.0	36